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Abstract. 2-Phenyl-4-quinolone series compounds have 
exhibited growth inhibitory influence on several human 
cancer cell lines. In this study, we investigated the effects of 
2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one 
(Smh-3) on viability, cell cycle and apoptotic cell death which 
occurred in different leukemia cell lines (HL-60, U937 and 
K562) in a dose- and time-dependent manner, but which did 
not obviously impair the viability of normal human umbilical 
vein endothelial cells (HUVEC) in vitro. The approximate 
IC50 was 103.26±4.59 nM for a 48 h treatment in HL-60 cells. 
Cell cycle analysis showed that 100 nM Smh-3 induced signi-
ficant G2/M arrest in examined cells. Within 0, 12, 24 and 48 h 
of treatment, Smh-3 inhibited CDK1 activity and decreased 
protein levels of CDK1, cyclin A and cyclin B. Smh-3-induced 
chromatin condensation and DNA fragmentation were 
determined by DAPI and TUNEL staining. Cell apoptosis was 
significantly reduced after pretreatment with a pan-caspase 
inhibitor (Z-VAD-fmk) and results indicated that Smh-3-
induced apoptosis was mainly mediated by activation of the 
caspase cascade in HL-60 cells. Results from colorimetric 
assays and Western blot analysis indicated that activities of 
caspase-9, -7 and -3 were promoted in Smh-3-treated HL-60 
cells during cell apoptosis. Smh-3-induced apoptosis in 
HL-60 cells was accompanied by an apparent increase in 
ROS production, and protein levels of cytosolic cytochrome c, 
apoptotic protease activating factor-1 (Apaf-1) and apoptosis-
inducing factor (AIF). Strikingly, Smh-3 induced apoptosis in 
HL-60 cells by simultaneously suppressing protein levels of 
AKT, p-AKT, p-mTOR and p-BAD and inducing BAD protein 
levels. Taken together, we conclude that Smh-3 acts against 
leukemia cells in vitro via G2/M phase arrest, down-regulation 
of AKT activity and induction of mitochondrial-dependent 
apoptotic pathways.
Introduction
Leukemia is one of the hematologic malignancies in human 
population. About 4.0 per 100,000 people die of leukemia each 
year in Taiwan based on the report of the Department of Health, 
R.O.C. (Taiwan) in the 2009 report (http://www.doh.gov.tw/
EN2006/index_EN.aspx). Leukemia involves progressive 
disruption of cell differentiation, proliferation and apoptosis 
(1). Bone marrow transplant, radiotherapy and chemotherapy 
are applied for the treatment of leukemia patients (2). 
The novel synthesized compounds, designed for providing 
chemotherapeutic effectiveness, are not detrimental to normal 
cells, which exert specific cytotoxic effects on leukemia cells 
through cell cycle arrest and apoptosis (3). Cyclin-dependent 
protein kinases (CDKs) and cyclins play important regulatory 
roles in cell cycle transition (4). Particularly, G2-M transition 
is regulated by cyclin-dependent protein kinase 1 (p34cdc2; 
CDK1) and cyclins A, B (5). Apoptosis is characterized by a 
series of morphological changes involving cell shrinkage and 
chromatin condensation (6). At least, two distinct pathways 
are involved in apoptotic cell death. The intrinsic pathway 
involves disrupting the mitochondrial membrane and releasing 
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cytochrome c, Apaf-1, AIF and pro-caspase-9 into the cytosol. 
The extrinsic pathway of apoptosis requires death receptors 
and ligand interaction such as FasL/Fas, TNF/TNFR and then 
to activate downstream caspase-8 (7-9). Both intrinsic and 
extrinsic pathways induce the activation of caspase-7 and -3 (10). 
A recent study has also demonstrated that the BCL-2 family 
proteins such as BAD can regulated mitochondria-mediated 
apoptotic pathway (11). It is thought that the ability of BAD to 
bind to BCL-2 is abrogated when BAD becomes phosphorylated 
at Ser136 by AKT protein kinase (12,13). 
In the present study, we have designed and synthesized a 
series of 2-phenyl-4-quinolone compounds as novel anti-
leukemia agents. 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1 
-yl)quinolin-4-one (Smh-3), as shown in Fig. 1, is a most 
potential candidate for anti-leukemia activities. However, neither 
the cytotoxic effects of Smh-3 on leukemia cells and normal 
cells, nor the molecular mechanisms underlying its anticancer 
activity have been investigated. Therefore, this study investigated 
the molecular mechanisms of Smh-3 in anti-leukemia effects 
on HL-60 cells in vitro. 
Materials and methods 
Chemicals and reagents. Smh-3 (2-(3-(methylamino)phenyl) 
-6-(pyrrolidin-1-yl) quinolin-4-one; Fig. 1) was synthesized in 
our laboratory, Graduate Institute of Pharmaceutical Chemistry, 
College of Pharmacy, China Medical University. Propidium 
iodide (PI), RNase A, Triton X-100 and proteinase K were 
purchased from Sigma Chemical Co. (St. Louis, MO). The 
Z-VAD-fmk (a pan-caspase inhibitor) was purchased from 
R&D Systems (Minneapolis, MN, USA). Sources of antibodies 
used in this study were as follows: polyclonal antibodies 
specific for phospho-GSK-3 α/β (Ser219), phospho-AKT 
(Ser473), phospho-mTOR (Ser 2481), phospho-BAD (Ser136), 
caspase-8, -9, -7 and -3 were obtained from Cell Signaling 
Technology Inc. (Danvers, MA, USA) and monoclonal 
antibodies specific for cyclin B, CDK1, cyclin A, cytochrome 
c, Apaf-1, AKT, mTOR, BAD and actin and all peroxidase-
conjugated secondary antibodies were obtained from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Monoclonal 
antibodies specific for AIF was purchased from Abcam Inc. 
(Cambridge, MA, USA). Enhanced chemiluminescence (ECL) 
was purchased from Pierce Chemical (Rockford, IL, USA). 
Cell culture. The leukemia cell lines HL-60 (human promye-
locytic leukemia), U937 (human lymphoma cancer cell), 
K562 (human chronic myelogenous leukemia), and HUVEC 
(human umbilical vein endothelial cells) were purchased 
from Culture Collection and Research Center (CCRC), Food 
Industry Research and Development Institute (Hsinchu, 
Taiwan). Cells were cultured in RPMI-1640 medium (Invitrogen, 
Carlsbad, CA, USA) and supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (HyClone, Logan, UT, USA), 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine 
at 37˚C in a 5% CO2 humidified incubator. The HUVEC were 
passaged at preconfluent densities using a solution containing 
0.05% trypsin and 0.5 mM EDTA (Invitrogen) (13).
Determinations of cell viability. Cells (2.5x105/well) were 
seeded in each well of 24-well plates and incubated with 0, 50, 
100, 200 and 400 nM Smh-3 for 0, 24 and 48 h. Cells were 
harvested, washed and re-suspended with phosphate-buffered 
saline (PBS) containing 4 µg/ml PI, and then analyzed by using 
a PI exclusion method and flow cytometry (FACSCalibur™, 
Becton-Dickinson, NJ, USA) equipped with a laser at 488 nm 
wavelength. The percentage of cell viability was calculated as 
a ratio of the number of Smh-3-treated cells to that of 0.1% 
DMSO as a vehicle-control group (14,15). Viability assays 
were performed in tr iplicate from three independent 
experiments. The 50% inhibitory concentration (IC50) of 
Smh-3 was calculated using the software of dose-effect 
analysis with microcomputers as described previously (13).
Cell morphology. HL-60 cells (2x105 cells/well) were maintained 
in 24-well plates with RPMI-1640 medium and then were 
treated with 0, 50, 100 and 200 nM of Smh-3. Cell morphology 
was examined and photographed under a phase contrast 
microscope. Chromatin condensation was detected using 
the DAPI (4,6-diamidino-2-phenylindole dihydrochloride) 
staining method. HL-60 cells were treated with 100 nM 
Smh-3 for 0, 12, 24 and 48 h. After incubation for the indicated 
time, HL-60 cells were fixed gently by putting 70% ethanol, 
stained with DAPI, and then photographed using a fluorescence 
microscope as described previously (14,16).
DNA content and cell cycle distribution analysis. HL-60 cells 
were seeded in 24-well cell culture plates at a density of 
2.5x105 cells/well, and incubated with 100 nM Smh-3 for 0, 
12, 24 and 48 h. For determination of cell cycle phase and 
apoptosis, cells were fixed gently by putting 70% ethanol in 
-20˚C overnight, and then re-suspended in PBS containing 
40 µg/ml PI, 0.1 mg/ml RNase and 0.1% Triton X-100 in dark 
room for 30 min. Cell cycle distribution and apoptotic nuclei 
were determined by flow cytometry as described previously 
(13,17).
CDK1 kinase assay. CDK1 kinase activity was analyzed 
according to the protocol of Medical & Biological Laboratories 
CDK1 kinase assay kit (MBL International, Nagoya, Japan). 
In brief, the ability of cell extract prepared from each treatment 
was measured to phosphorylate its specific substrate, MV 
peptide as described previously (13,18).
TUNEL assay. HL-60 cells were seeded in 24-well cell culture 
plates at a density of 2.5x105 cells/well, and then incubated 
with 100 nM Smh-3 for 0, 24, 48 and 72 h. For the specific 
inhibitor assay, cells were seeded in 24-well plates, and then 
pretreated with a pan-caspase inhibitor (Z-VAD-fmk) for 1 h, 
followed by treatment with or without 100 nM Smh-3. After 
incubation for the indicated time, in situ apoptosis detection of 
DNA fragmentation was determined by using a terminal deoxy- 
ribonucleotide transferase-mediated dUTP nick-end labeling 
(TUNEL) assay (Roche Diagnostics, Hillsdale, MI, USA). 
Following TUNEL staining, all samples were washed once 
and re-suspended in 0.5 ml of PBS containing PI (10 µg/ml) 
and DNase free-RNase A (200 µg/ml). TUNEL positive cells 
were analyzed by flow cytometry. The median fluorescence 
intensity was quantified by BD Pro CellQuest software. TUNEL 
assays were performed in triplicate from three independent 
experiments as described previously (13).
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Caspase activity assay. HL-60 cells (2.5x106 cells/well) were 
seeded in 6-well cell culture plates and incubated with 100 nM 
Smh-3 for 48 h. Cells were lysed in lysis buffer (50 mM 
Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM EGTA, 10 mM 
digitonin and 2 mM DTT). About 50 µg of cytosol proteins 
were incubated with caspase-9, -8, -7 and -3 specific substrates 
(R&D System) for 1 h at 37˚C. The caspase activity was deter-
mined by measuring OD 405 as described previously (19). 
Western blotting. HL-60 cells were seeded in 10 cm-dishes at 
an initial concentration of 1x107 cells and incubated with 
100 nM Smh-3 for 0, 12, 24 and 48 h. Cytosolic fraction and 
total protein were prepared and determined. Equal amounts of 
protein (30 µg) were separated by 10-12% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and 
electro-transferred to a nitrocellulose membrane by using iBot™ 
Dry Blotting System (Invitrogen). Blots were blocked in PBST 
buffer (0.05% Triton X-100 in PBS) containing 5% non-fat 
milk for 1 h, and incubated with specific primary antibodies 
at 4˚C overnight. The membrane was washed with PBST 
buffer and incubated with secondary antibodies conjugated 
horseradish peroxidase (HRP). The specific protein was detected 
by using enhanced chemiluminescence kits (Amersham, ECL 
Kits) as described previously (13,19).
Determination of reactive oxygen species (ROS). Approximately 
2x105 cells/well of HL-60 cells in 24-well plates were treated 
with 100 nM Smh-3 and incubated for 0, 3, 6, 12 and 24 h. At 
the end of incubation, cells from each treatment were harvested 
by centrifugation, washed twice by PBS, and then re-suspended 
in 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; 10 µM) 
for ROS determination. Cells were incubated for 30 min at 37˚C 
in the dark room and analyzed immediately by flow cytometry 
as described previously (15,19).
In vitro cell AKT kinase assay. This assay was performed 
followed as the protocol of the manufacturer's instructions 
from an AKT kinase assay Kit (Cell Signaling Technology, 
Beverly, MA, USA). In brief, about 1x106 cells/well of HL-60 
cells in a 75-T flask were treated with 0, 50, 100, 200 and 
400 nM of Smh-3 for 2 h. Cells were then harvested, washed 
twice with PBS, and lyzed in ice-cold lysis buffer provided in 
this kit. The 200 mg of protein from each time-point treatment 
were immunoprecipitated with 2 mg of anti-AKT antibody 
overnight. All samples were extensively washed, and then the 
immunoprecipitates were incubated with 1 mg of glycogen 
synthase kinase-3 α/β (GSK-3 α/β) fusion protein substrate in 
50 µl of kinase buffer for 30 min at 30˚C. Reactions were 
stopped with SDS loading buffer. The samples were separated 
on 12% SDS-PAGE, and the phospho-GSK-3 α/β (Ser219) was 
detected by immunoblotting (20).
Statistical analysis. Data are presented as the mean ± SEM 
for the indicated number of separate experiment. Statistical 
analyses of data were performed by Student's t-test, and 
*P<0.05, ***P<0.001 were considered significant. 
Results
Smh-3 inhibited cell growth of human leukemia cells. Initially, 
cells were determined the growth inhibition effects of Smh-3 
on cell viability by using a PI exclusion assay and flow cytometric 
analysis. As shown in Fig. 2A, Smh-3 inhibited cell growth of 
Figure 1. Chemistry structure of Smh-3 (2-(3-(methylamino)phenyl) 
-6-(pyrrolidin-1-yl) quinolin-4-one).
Figure 2. Effects of Smh-3 on cell viability and morphological changes in 
human leukemia cell lines. Human leukemia cells (HL-60, U937 and K562) 
and HUVEC were treated with 0, 50, 100 nM of Smh-3 for 48 h and then cell 
viability was determined by a PI exclusion method and flow cytometry (A). 
HL-60 cells were exposed to 0, 50, 100, 200 and 400 nM of Smh-3 for 0, 24, 
48 and 72 h, and cell viability was determined and measured (B). The data 
shown are mean ± SEM of three independent experiments. ***P<0.001 vs. 
0 nM treatment. Cells were treated with 0, 50, 100 and 200 nM of Smh-3 for 
48 h, and photographed under a phase-contrast microscope at a magnification 
x200 (C).
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HL-60, U937 and K562 cells in a dose-dependent manner. 
Smh-3 shows much less cytotoxic effect on the normal HUVE 
than that on HL-60 cells as compared this effect of Smh-3 on 
HL-60 to normal HUVEC cells (Fig. 2A). Smh-3 inhibited cell 
growth of HL-60 cells in a dose- and time-dependent manner 
(Fig. 2B). The half maximal inhibitory concentration IC50 for 
48 h treatment of Smh-3 in HL-60 cells was 103.26±4.59 nM. 
It can be seen in Fig. 2C and indicated that Smh-3 induced 
cell morphological changes, and decreased the cells number 
in HL-60 cells. Apoptotic HL-60 cells showed smaller, round 
and blunt in size after Smh-3 exposure, and these effects are 
dose-dependent (Fig. 2C). 
Smh-3 induced G2/M phase arrest by decrease CDK1 activity 
in HL-60 cells. We investigated the possible mechanisms and 
whether Smh-3 is able to promote cell cycle arrest in HL-60 
cells. As shown in Fig. 3, 100 nM Smh-3 induced cell cycle 
arrest in G2/M phase in HL-60 cells and this effect was time-
dependent. We also examined the CDK1 activity in 
Smh-3-treated HL-60 cells. Results shown in Fig. 4A indicate 
that Smh-3 caused a significant decrease in CDK1 activity for 
12, 24, and 48 h treatment. We characterized the cell cycle-
regulated protein levels in G2/M phase. As shown in Fig. 4B, 
Smh-3 caused a decrease the protein levels of cyclins A, B and 
CDK1 in HL-60 cells. Our results suggest that cyclins A, B 
and CDK1 activities play important roles in G2/M phase arrest 
in Smh-3-treated HL-60 cells.
Smh-3 induced chromatin condensation and DNA fragmentation 
in HL-60 cells. To investigate the incidence of chromatin 
condensation in Smh-3-treated HL-60 cells, we assessed the 
nuclear chromatin changes by DAPI staining. As shown in 
Fig. 5A, cells exhibited nuclear shrinkage and chromatin 
condensation after incubation with 100 nM Smh-3 for 12, 24 
and 48 h. We also demonstrated that Smh-3 induced DNA 
fragmentation which was examined by TUNEL staining and 
flow cytometric analysis as shown in Fig. 5B. Smh-3 induced 
DNA fragmentation (TUNEL positive cells) in HL-60 cells 
and this response was increased in a time-dependent manner. 
Based on our results, it is suggested that Smh-3 induced 
chromatin condensation and DNA fragmentation for cell 
apoptosis in HL-60 cells in vitro.
Smh-3 stimulates the activities of caspase-3, -7 and -9 in 
HL-60 cells. To verify if caspase activity is involved in 
Smh-3-induced apoptosis in HL-60 cells, the cells were 
pretreated with 10 µM Z-VAD-fmk (a pan-caspases inhibitor) 
and exposed to 100 nM Smh-3. The cells were harvested for 
measuring the TUNEL positive cells by flow cytometric 
assay. The results are shown in Fig. 6A and revealed that 
Z-VAD-fmk decreased the percentage of TUNEL positive 
cells in Smh-3-treated HL-60 cells. Our finding indicated that 
Smh-3-induced apoptosis was through an increase of caspase 
activity. To examine whether Smh-3-induced apoptosis is 
involved in the activations of caspase cascades, cells were 
harvested after exposure to 100 nM Smh-3 and then the 
Figure 3. Smh-3 promotes G2/M phase arrest in HL-60 cells. Cells were 
treated with 100 nM Smh-3 for 0, 12, 24 and 48 h, and then harvested for cell 
cycle distribution by flow cytometry (A). Bar graph representation of the 
percentage in different phases of the cell cycle distribution (B). Figure 4. Smh-3 inhibits CDK1 activity and affects G2/M phase-associated 
protein levels in HL-60 cells. Cells were treated with 100 nM Smh-3 for 0, 
12, 24 and 48 h, and then harvested for examining the CDK1 activity (A). 
Cells were incubated with 100 nM Smh-3 for 0, 12, 24 and 48 h and then 
harvested, total protein was lysed for the detection of the protein levels of 
cyclins A, B and CDK1 by Western blot analysis (B).
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activities of caspase-3, -7, -8 and -9 were determined by 
colorimetric assays or examined the protein levels of caspase-3, 
-7, -8 and -9 by Western blotting. As shown in Fig. 6B, 
Smh-3 promoted the activation of caspase-3, -7 and -9, but not 
caspase-8 after 48 h treatment. Therefore, Smh-3 increased 
the active form levels of caspase-3, -7 and -9 in a time-
dependent manner (Fig. 6C). Our results suggest that 
Smh-3-triggered apoptosis may be mediated through mito-
chondria-dependent signaling pathway in HL-60 cells.
Smh-3 induced production of reactive oxygen species (ROS) 
and release of the apoptosis-associated proteins in HL-60 
cells. To verify if ROS are involved in Smh-3-induced apoptosis 
in HL-60 cells, the cells were exposed to 100 nM Smh-3 for 
0, 3, 6, 12 and 24 h, and then harvested for measurement in 
the level of ROS production by flow cytometric assay. The 
results in Fig. 7A indicated that Smh-3 promoted the ROS 
production from 3 to 24 h time-dependently. Smh-3 (100 nM) 
increased the protein levels of cytosolic cytochrome c, AIF 
and Apaf-1 (Fig. 7B). Our results indicated that Smh-3-induced 
cell death may be mediated through the mitochondria-
dependent apoptotic signaling pathways in HL-60 cells.
Smh-3 inhibited the activity of AKT and down-regulated the 
expression of phospho-BAD in HL-60 cells. To examine the 
involvement of AKT pathway in Smh-3-regulated apoptosis 
in HL-60 cells, we assessed the effects of Smh-3 on AKT 
activity at 0, 50, 100, 200 and 400 nM of Smh-3 for 2 h 
treatment. The protein levels of phospho-AKT and phospho-
mTOR after treatment with 100 nM of Smh-3 for 0, 1, 2 and 
4 h were investigated. Our results in Fig. 8A show that Smh-3 
Figure 5. Smh-3 induced chromatin condensation and DNA fragmentation 
in HL-60 cells. For detecting chromatin condensation, cells were treated 
with 100 nM Smh-3 for 0, 12, 24 and 48 h, and were stained by DAPI 
staining as described in Materials and methods (A). The DNA fragmentation 
was determined by TUNEL assay and analyzed by flow cytometry (B). 
The data shown are the mean ± SEM of three independent experiments. 
***P<0.001 vs. 0 h treatment.
Figure 6. Smh-3 increased the caspase-3, -7 and -9 activities and protein levels 
in HL-60 cells. Cells were pretreated with or without 10 µM pan-caspase 
inhibitor (Z-VAD-fmk) and then were treated with 100 µM Smh-3 for 48 h. 
The apoptotic cells were determined by TUNEL assay and analyzed by flow 
cytometry (A). Cells were treated with 100 nM Smh-3 for 48 h and the 
whole-cell lysate was subjected to caspase-3, -7, -9 and -8 activity assay (B). 
The data shown are mean ± SEM of three independent experiments. 
***P<0.001 vs. control. Cells were treated with 100 nM Smh-3 for 0, 12, 24 
and 48 h, and then harvested total protein lysed for the detection the protein 
levels of caspase-8, -9, -3 and -7 by Western blot analysis (C).
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decreased the AKT activity after treatment with 50 to 400 nM 
of Smh-3 and this effect is dose-dependent. In Fig. 8B, results 
from Western blot analysis show that Smh-3 caused a decrease 
in protein levels of phospho-AKT, AKT, phospho-mTOR and 
mTOR in HL-60 cells. It is reported that BAD is a major 
regulator of AKT signaling (10), we next determined the effect 
of Smh-3 on the protein levels of BAD and phospho-BAD in 
HL-60 cells. As seen in Fig. 8C, we found an increase in the 
expression of BAD, but a decrease in the expression of 
phospho-BAD in a time-dependent manner. Our data suggest 
that Smh-3-affected apoptotic cell death in HL-60 cells is 
through inhibition of the AKT activity, leading to the decrease 
in the level of phospho-BAD protein. 
Discussion
Several reports have been demonstrated that 2-phenyl-4-
quinolones series compounds exhibited growth inhibitory 
effects on several human cancer cell lines (18,21). 2-phenyl-4-
quinolone series compounds might inhibit CDK1 activity and 
act as anti-mitotic agents (18). In recent years, we have designed 
and synthesized a new series of 2-phenyl 6-pyrrolidinyl-4-
quinazolinone derivatives as new anti-leukemia agents and 
Smh-3 (Fig. 1) (2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)
quinolin-4-one) is the most potential compound against cancer 
cells in vitro. However, the growth inhibition effects of Smh-3 
on leukemia cells and normal cells or the molecular mechanisms 
underlying its anti-leukemia activity have not been clarified. In 
this study, we first demonstrated that Smh-3 induced growth 
Figure 7. Smh-3 enhances the ROS production and affects the apoptosis-
associated protein levels of mitochondria-dependent pathway in HL-60 cells. 
Cells were treated with 100 nM Smh-3 for 0, 3, 6, 12 and 24 h. The level of 
ROS production was stained with 2,7-dichlorodihydrofluorescein diacetate 
(DCFH-DA). The stained cells were determined by flow cytometry as 
described in Materials and methods (A). Cells were treated with 100 nM 
Smh-3 for 0, 12, 24 and 48 h and then harvested cytosolic lysate for the 
detection the protein levels of cytochrome c, Apaf-1 and AIF by Western blot 
analysis (B). The data shown are mean ± SEM of three independent experiments. 
***P<0.001 vs. 0 h treatment.
Figure 8. Smh-3 inhibits the AKT activity and affects the BAD protein level 
in HL-60 cells. Cells were treated with 0, 50, 100, 200 and 400 nM of Smh-3 
for 2 h and then were harvested for examining the AKT activity as described 
in Materials and methods (A). Cells were treated with 100 nM of Smh-3 for 
0, 1, 2 and 4 h, and then harvested total protein lysed for the detection the 
protein levels of AKT, p-AKT, mTOR, p-mTOR (B) and p-BAD, BAD (C) by 
Western blot analysis. The data shown are mean ± SEM of three independent 
experiments. ***P<0.001 vs. 0 h or 0 nM treatment.
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inhibitory effects through G2/M phase arrest (Fig. 3) and 
induction of apoptosis (Fig. 5) in HL-60 cells. Moreover, Smh-3 
has much less cytotoxic effect on HUVEC than that on HL-60 
cells (Fig. 2A). It is important for Smh-3 to be used in leukemia 
patients with decreasing side-effects. 
We selected the closest concentration to IC50 (100 nM) 
of Smh-3 for determining anti-leukemia activity. Results are 
summarized as follows: i) HL-60 cells were treated with 
Smh-3 for 12-48 h, causing G2/M arrest (Fig. 3). ii) Smh-3 
decreased CDK1 activity as well as protein levels of cyclins A, 
B and CDK1 in HL-60 cells (Fig. 4). iii) Smh-3 caused 
activation of caspase-9, -7 and -3 in HL-60 cells (Fig. 6). iv) 
Smh-3 caused a decrease in AKT activity and protein levels 
after 2 h treatment in HL-60 cells (Fig. 8). v) Smh-3 down-
regulated the protein level of p-BAD and up-regulated protein 
levels of cytosolic cytochrome c, AIF and Apaf-1 in HL-60 
cells (Figs. 7 and 8). Taken together, we suggest that Smh-3 
induced apoptotic cell death through the mitochondria-
dependent apoptotic pathway by inhibiting AKT activity in 
HL-60 cells. 
Our results showed that Smh-3 promoted the ROS production 
in HL-60 cells and this effect is time-dependent (Fig. 7A). 
HL-60 cells were pretreated with ROS scavenger, 10 mM 
NAC, which led to increase in the viable HL-60 cells when 
compared to the only Smh-3-treated cells (data not shown). The 
results suggest that ROS production may be involved in 
Smh-3-induced apoptotic cell death in HL-60 cells. The 
consistence of our data with our previous reports demonstrating 
that 2-phenyl-4-quinolone series compound induced apoptosis 
via ROS-dependent mitochondrial death pathway in human 
osteogenic sarcoma U-2 OS cells (22). When mitochondria 
receive an apoptotic signal, the outer membrane of mitochondria 
becomes permeabilized, and then cytochrome c, Apaf-1, 
procaspase-9, and AIF are released into the cytosol, activating 
caspase-3 and -7 by caspase-9, leading to apoptosis (23-25). 
Smh-3 induced the activation of caspase-9, -7 and -3 after 48 h 
treatment (Fig. 6), suggesting that Smh-3 may possibly activate 
intrinsic signaling pathways. Our results demonstrated an 
increase of ROS production after Smh-3 treatment for 3 h 
(Fig. 7), and then promoted the release of cytochrome c, 
Apaf-1 and AIF protein levels from mitochondria into the 
cytosol (Fig. 7). In addition, caspase-8 activity in Smh-3-treated 
HL-60 cells had no significant increase (Fig. 6). Based on the 
above evidence (Fig. 6), we might rule out that Smh-3-
stimulated apoptotic cell death is involved in the extrinsic 
apoptotic pathway.
BCL-2 family proteins are classified into the following 
three categories according to their function: i) proteins were 
involved in inhibiting apoptosis: such as BCL-2, BCL-xL; 
ii) proteins were involved in promoting apoptosis: such as 
Bax, Bid; iii) BH3-only protein: such as BAD (23-25). BAD is 
activated by dephosphorylation, and has a conserved BH3 
domain that binds and regulates the anti-apoptotic protein to 
promote cell apoptosis (10). Considerable evidence indicates 
that BAD can affect Bax by directly binding and inhibiting 
BCL-2 (26,27). Our study suggests that BAD was dephos-
phorylated and activated after HL-60 cells were treated with 
Smh-3 (Fig. 8C), which may lead to activation of Bax and 
inactivation BCL-2, then triggering apoptosis. It has been 
reported that AKT is involved in survival signaling pathway 
by phosphorylating BAD (11). The phospho-BAD bound to 
14-3-3 proteins, but not BCL-2. In the present study, we 
demonstrated that Smh-3 inhibited the activity of AKT in 
HL-60 cells (Fig. 8A and B), leading to that BAD was 
reported to be deposphorylated and then induced apoptosis in 
Smh-3-treated HL-60 cells (11,28).
Overall, the molecular signaling pathways are summarized 
in Fig. 9. Our results demonstrated that Smh-3 exposure causes 
G2/M phase arrest and inhibits AKT activity in HL-60 cells. 
Dephosphorylation of BAD promotes the releases cytochrome c, 
Apaf-1, AIF from mitochondria to cytosol which activates 
caspase-9, -7 and -3, leading to apoptosis. Hence, Smh-3 could 
possibly be used as a novel therapeutic agent for the treatment of 
leukemia in the future.
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